He is a medical oncologist with expertise in clinical. After graduating in Brazil, he moved to Spain for training in phase 1 development of cancer drugs, with focus on colorectal cancer. He helped develop a molecular pre screening strategy to match the genomic profile of each patient’s tumor to targeted agents, the central dogma of Precision Medicine. During my post-graduation at the Massachusetts General Hospital, he provided standardized decision support with structured reports of the next-generation sequencing tests performed at the clinical lab. By designing the framework for variant annotation, prioritization and interpretation, together with a comprehensive gene-drug knowledge database of predictive genomic biomarkers in solid tumors, he had a central role in the process of clinical implementation of these tests. He then assisted the Sage Bionetworks Computational Oncology team in the development of predictive and prognostic models using cancer omics data.

He was deeply involved in the Colorectal Cancer Subtyping Consortium, which led to the identification and clinico-molecular characterization of the consensus molecular subtypes (CMS). During the last years he has collaborated with many academic groups working on clinical translation of CMS groups, including in depth analysis of their prognostic and predictive values. Currently, in addition to his position as leader of the Oncology Data Science Group and Molecular Prescreening Program of Vall d’Hebron Institute of Oncology (Spain), he is a medical director of Oncoclínicas Precision Medicine and Big Data Initiative, in São Paulo (Brazil).